Location [1]
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
Proto-oncogene tyrosine-protein kinase ROS
Synonyms [1]
ROS, MCF3, c-ros-1

ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) is a gene that encodes the proto-oncogene tyrosine-protein kinase ROS protein, a receptor tyrosine kinase (RTK) of the insulin receptor family. ROS1 fusions have been described in glioblastoma (PMID: 2827175; PMID: 2352949; PMID: 12661006), non-small cell lung cancer (PMID: 18083107), and cholangiocarcinoma (PMID: 21253578). ROS1 fusions containing an intact tyrosine kinase domain possess oncogenic activity (PMID: 12661006PMID: 18083107). Signaling downstream of ROS1 fusions results in activation of cellular pathways known to be involved in cell growth and cell proliferation.

ROS1 is altered in 4.26% of all cancers with melanoma, non-small cell lung carcinoma, breast carcinoma, colorectal adenocarcinoma, and uterine corpus neoplasm having the greatest prevalence of alterations [3].

ROS1 GENIE Cases - Top Diseases

The most common alterations in ROS1 are ROS1 Mutation (4.12%), ROS1 Amplification (0.18%), ROS1 Loss (0.11%), ROS1 G1915R (0.03%), and ROS1 D1854N (0.02%) [3].

ROS1 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of ROS1 in Diseases

Non-Small Cell Lung Carcinoma +

Malignant Solid Tumor +

Non-Hodgkin Lymphoma +

Cancer +

Multiple Myeloma +

Lymphoma +

Melanoma +

Lung Carcinoma +

Colorectal Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Histiocytic And Dendritic Cell Neoplasm +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.